Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is entering a new drug approval harvest period with a well-structured pipeline covering ADC (Antibody-Drug Conjugates) and IO (Immuno-Oncology) [3][10]. - The company has multiple oncology product pipelines, including immune therapy, ADC targeted therapy, and oncolytic virus drugs, with several candidates in clinical stages [3][11]. - The company achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development and sales [3][25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, establishing a comprehensive ADC technology platform and has developed multiple ADC products, including PD-1 monoclonal antibody and MRG003 [11][14]. - The pipeline includes six ADC drugs, one oncolytic virus, and one TCE (T-cell Engager) drug in clinical stages, with several candidates entering pivotal trials [14][18]. Unique Features of ADC Candidates - MRG003 (EGFR ADC) has been approved for NPC (Nasopharyngeal Carcinoma) in China, showing superior survival benefits and safety compared to competitors [4][30]. - MRG004A (TF-ADC) is in Phase III trials for pancreatic cancer, while MRG006A (GPC3 ADC) targets the liver cancer market and is expected to enter Phase III trials in 2026 [6][30]. Oncolytic Virus and International Expansion - The company introduced the oncolytic virus therapy CG0070, which is in critical registration trials in China and has shown promising efficacy in the U.S. for bladder cancer [5][30]. - The company has successfully partnered for international expansion with MRG007 (CDH17 ADC) and CTM012 (CD3/4-1BB/DLL3 tri-antibody) [5][30]. Financial Projections and Investment Recommendations - Revenue projections for 2025, 2026, and 2027 are estimated at 880 million, 1.02 billion, and 1.49 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [6][30]. - The company is still in the investment phase for innovative drug development, with projected net profits of -20 million, 10 million, and 280 million yuan for the same years [6][30].

证券研究报告：电子 | 公司点评报告 发布时间：2026-01-27 股票投资评级 买入 |维持 个股表现 2025-01 2025-04 2025-06 2025-08 2025-11 2026-01 -15% -5% 5% 15% 25% 35% 45% 55% 65% 75% 甬矽电子 电子 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 46.37 | | --- | --- | | 总股本/流通股本（亿股）4.10 | / 4.10 | | 总市值/流通市值（亿元）190 | / 190 | | 52 周内最高/最低价 | 52.21 / 24.06 | | 资产负债率(%) | 70.4% | | 市盈率 | 289.81 | | 第一大股东 | 浙江甬顺芯电子有限公 | | 司 | | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 甬矽电子(688362) 先进封装、海外客户占比 ...

证券研究报告：宏观报告 研究所 分析师:李起 SAC 登记编号:S1340524110001 Email:liqi2@cnpsec.com 研究助理:高晓洁 SAC 登记编号:S1340124020001 Email:gaoxiaojie@cnpsec.com 近期研究报告 《高频数据显示生产和外需平稳，投资 增速改善仍需观察》 - 2026.01.26 宏观观点 海外宏观周报：美联储降息将按下暂停键 ⚫ 核心观点： 上周达沃斯论坛释放的信号强化了投资者对全球增长不确定性 与风险溢价上行的定价，黄金价格显著走高，反映出宏观与地缘因素 仍是当前资产配置的重要约束。预计欧洲的国防及战略自主能力将逐 步增强。 货币政策方面，在去年下半年连续三次风险管理式降息后，本周 美联储议息会议或将迎来首次暂停。在即将到来的会议上，鲍威尔主 席可能会强调，FOMC 刚刚进行了三次降息，对当前的货币政策立场感 到满意，并不急于进一步调整利率。预计鲍威尔会重申货币政策将依 赖后续的数据灵活决策，同时表示现行利率水平仅具有轻微的紧缩效 果。重点应关注鲍威尔对美国就业形势的判断。往后看，我们认为， 美国当前呈现的 K 型经济结构并不支持 ...

证券研究报告：电子 | 公司点评报告 发布时间：2026-01-27 股票投资评级 买入 |维持 个股表现 2025-01 2025-04 2025-06 2025-08 2025-11 2026-01 -15% -5% 5% 15% 25% 35% 45% 55% 65% 75% 甬矽电子 电子 资料来源：聚源，中邮证券研究所 公司基本情况 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 甬矽电子(688362) 先进封装、海外客户占比持续提升 l 投资要点 盈利能力逐步显现，先进封装占比提升。公司预计 2025 年年 度实现营收 42-46 亿元，同比增加 16.37%至 27.45%，归母净利润 0.75-1 亿元，同比增加 13.08%至 50.77%。报告期内，全球半导体 产业在人工智能、高性能计算、数据中心基础设施建设等需求的拉 动下，延续增长态势。得益于海外大客户的持续放量和国内核心端 侧 SoC 客户群的成长， ...

Investment Rating - The report assigns a "Buy" rating for the company, Lepu Biopharma (2157.HK), marking its first coverage [1]. Core Insights - The company is entering a harvest period for new drug approvals, having established a comprehensive pipeline in oncology that includes immunotherapy, ADC (Antibody-Drug Conjugate) targeted therapy, and oncolytic virus drugs. The company has multiple ADC drugs and other therapies in clinical stages, with expectations for new drug approvals in the next 3-5 years [3][10]. - The ADC pipeline is characterized by unique features and competitive advantages in various indications, with MRG003 (EGFR ADC) already approved for NPC (nasopharyngeal carcinoma) in China and showing promising results in other indications [4][30]. - The introduction of oncolytic virus therapy CG0070 has shown potential in the bladder cancer market, with successful regulatory progress in the U.S. and ongoing clinical trials in China [5][30]. - Financially, the company has achieved its first profit and positive operating cash flow in the first half of 2025, with steady revenue growth driven by business development and sales [25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, with a pipeline that includes immunotherapy, ADCs, and oncolytic virus therapies. It has developed a robust ADC technology platform and has multiple products in various stages of clinical development [11][10]. - The pipeline includes 6 ADC drugs and 1 oncolytic virus therapy, with several candidates in pivotal clinical stages, indicating a well-structured development strategy [14][10]. Unique Features of ADCs - MRG003 has been approved for NPC and is in advanced trials for HNSCC (head and neck squamous cell carcinoma) and NSCLC (non-small cell lung cancer), showcasing its broad applicability and competitive edge [30][4]. - Other ADCs in development, such as MRG004A for pancreatic cancer and MRG006A for liver cancer, are also progressing well, with MRG004A entering pivotal trials [30][6]. Financial Performance and Projections - The company reported revenues of 4.66 billion yuan in the first half of 2025, a significant increase from 1.33 billion yuan in the same period of 2024. The net profit for the same period was 290 million yuan, marking a turnaround from a loss of 197 million yuan in the previous year [25][30]. - Revenue projections for 2025, 2026, and 2027 are estimated at 8.8 billion yuan, 10.2 billion yuan, and 14.9 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [30].

证券研究报告：电子 | 公司点评报告 股票投资评级 买入 |维持 公司基本情况 | 最新收盘价（元） | 28.83 | | --- | --- | | 总股本/流通股本（亿股）4.02 | / 4.02 | | 总市值/流通市值（亿元）116 | / 116 | | 52 周内最高/最低价 | 30.61 / 18.01 | | 资产负债率(%) | 15.8% | | 市盈率 | 68.64 | | 第一大股东 | 王亚龙 | 市场有风险，投资需谨慎 请务必阅读正文之后的免责条款部分 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 莱特光电(688150) 巩固 OLED 有机材料优势，布局 Q 布及钙钛矿市场 l 投资要点 8.6 代线投产释放 OLED 材料需求，国产替代加速推动。京东方 8.6 代高端触控 OLED 产线于 2025 年 12 月 30 日成功点亮，较计划提 前 5 个月。该产线主供笔记本电脑 ...

证券研究报告：固定收益报告 发布时间：2026-01-27 研究所 分析师:梁伟超 SAC 登记编号:S1340523070001 Email:liangweichao@cnpsec.com 研究助理:王一 SAC 登记编号:S1340125070001 Email:wangyi8@cnpsec.com 近期研究报告 《债市修复到位了吗？ ——流动性周 报 20260125》 - 2026.01.26 固收专题 1 月收官，政府债供给压力如何？ ⚫ 规模与节奏：前置发力回归，增量主要来自地方债 2025 年在赤字率上调带动下，政府债净融资升至约 13.51 万亿元， 发行节奏整体平稳，国债重心偏向 5 至 7 月，地方债在 2 至 4 月与 7 至 9 月两段提速。2026 年 1 月政府债净融资约 1.16 万亿元，同比多约 2269.6 亿元，增量主要由地方债贡献，地方债净融资约 7294.4 亿元， 国债净融资约 4267.5 亿元。与历史均值相比，2026 年 1 月略偏高，开 年靠前发力回归，短期更需关注发行密度对资金面与承接情绪的扰动。 ⚫ 期限结构：国债中长端放量，地方债超长权重抬升 1 月国债 ...

证券研究报告：电子 | 公司点评报告 | 最新收盘价（元） | 28.83 | | --- | --- | | 总股本/流通股本（亿股）4.02 | / 4.02 | | 总市值/流通市值（亿元）116 | / 116 | | 52 周内最高/最低价 | 30.61 / 18.01 | | 资产负债率(%) | 15.8% | | 市盈率 | 68.64 | | 第一大股东 | 王亚龙 | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 莱特光电(688150) 巩固 OLED 有机材料优势，布局 Q 布及钙钛矿市场 l 投资要点 8.6 代线投产释放 OLED 材料需求，国产替代加速推动。京东方 8.6 代高端触控 OLED 产线于 2025 年 12 月 30 日成功点亮，较计划提 前 5 个月。该产线主供笔记本电脑、平板电脑等智能终端中尺寸高端 屏，是国内显示产业向中尺寸高画质 OLED 领域突破的关键落子。此 ...

| 最新收盘价（元） | 79.50 | | --- | --- | | 总股本/流通股本（亿股）2.40 | / 0.48 | | 总市值/流通市值（亿元）190 | / 38 | | 52 周内最高/最低价 | 102.65 / 42.12 | | 资产负债率(%) | 9.4% | | 第一大股东 | 虞仁荣 | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 研究助理:陈天瑜 SAC 登记编号:S1340125090015 Email:chentianyu@cnpsec.com 证券研究报告：电子 | 公司点评报告 股票投资评级 增持 |首次覆盖 个股表现 2025-06 2025-08 2025-09 2025-10 2025-12 2026-01 0% 14% 28% 42% 56% 70% 84% 98% 112% 126% 140% 新恒汇 电子 资料来源：聚源，中邮证券研究所 公司基本情况 新恒汇(301678) 芯联万物，智启未来 l 投资要点 2025 年前三季度营收同比增长，三季度单季增速进一步提升。 2025 ...

1. Report Industry Investment Rating No information provided in the content. 2. Core Viewpoints of the Report - The secondary perpetual bond market shows a distinct feature of "long - end leading the rise", with long - end yields falling significantly more than short - end yields. The long - term spread of secondary perpetual bonds has been repaired, forming a steep term spread compression pattern. Insurance institutions increase their allocation of 7 - 10 - year bonds, and funds increase their allocation of 3 - 5 - year bonds. [2][12] - After the structural differentiation market, the transmission from the long - end to the short - end is not smooth, and the downward momentum of the long - end is limited. The trading difficulty of medium - and long - term secondary perpetual bonds remains relatively large. It is recommended to use 3 - 5 - year varieties as the bottom position and wait for opportunities in the adjustment of relatively long - term varieties. [4][5] 3. Summary According to Relevant Catalogs 3.1 1. Market Review: Insurance Institutions Increase Allocation, and Long - Term Secondary Perpetual Bonds of Large Banks Have an Independent Market - **Yield Performance**: In the third week of January, the yields of secondary perpetual bonds decreased, with long - end varieties performing particularly prominently. The 7 - year and 10 - year yields of secondary capital bonds decreased by 9.61bp and 8.84bp respectively, while the 1 - year yield only decreased by about 1bp. Perpetual bonds showed a similar pattern. In contrast, the long - end yields of other credit bonds such as medium - and short - term notes and commercial financial bonds decreased more moderately. [12] - **Spread Compression**: The credit spread quantiles of secondary perpetual bonds generally showed a compression trend, and the long - term spread repair of secondary perpetual bonds was the most prominent. The 10 - year and 7 - year spread quantiles of secondary capital bonds decreased by 20.70 and 15.61 percentage points respectively. The 7Y - 5Y term spread quantile decreased significantly, indicating a greater decline in the 7 - year yield and an obvious increase in the preference of allocation funds for this term variety. [16] - **Institutional Allocation**: Insurance institutions increased their allocation of 7 - 10 - year and 20 - 30 - year bonds, with net purchases of 12.44 billion yuan and 42.66 billion yuan respectively. Fund institutions' net purchases were mainly concentrated in the medium - and long - end, with a large - scale net purchase of 243.13 billion yuan in the 3 - 5 - year period. Other institutions had different allocation and reduction behaviors. [17] - **Transaction of Individual Bonds**: The trading of 7 - year secondary capital bonds was concentrated in state - owned banks, with Agricultural Bank of China and China Construction Bank accounting for more than 90%. The representative bonds of the two banks had significant trading volumes and their yields decreased. [19] 3.2 2. Outlook: Limited Transmission from the Long - End to the Short - End, and Relatively Large Trading Difficulty - **Analysis of Historical Market Conditions**: Five periods of similar duration differentiation market conditions since 2022 were selected. In these periods, long - term bonds generally had a greater decline in yields than short - term bonds. After that, the transmission from the long - end to the short - end was not smooth, and the long - end's downward momentum was limited. [23] - **Market Outlook**: The differentiation of spread quantiles is usually a leading signal for market differentiation. When secondary capital bond yields show a structural differentiation where long - term varieties decline more than short - term ones, there is no smooth transmission from long - to medium - and short - term bonds. Short - end yields are at relatively low historical quantiles, with limited downward space and low allocation cost - effectiveness. In a non - bull market environment, it is difficult for secondary perpetual bonds to achieve a rotation between long and short market conditions after term spread compression, and the subsequent trend of long - term secondary perpetual bonds is more likely to be volatile. [29][30] - **Trading Suggestions**: Since the end of 2025, the short - end yield and credit spread quantiles of secondary capital bonds have decreased significantly, while the long - term yield quantiles have remained around 50% and the credit spread quantiles around 80%. Although there is no obvious supply pressure for long - term secondary perpetual bonds and moderately lengthening the duration has certain feasibility, the trading difficulty is still relatively large. It is recommended to use 3 - 5 - year varieties as the bottom position and wait for adjustment opportunities in relatively long - term varieties. [32][33]